J
José Luis González-Larriba
Researcher at Hospital Clínico San Carlos
Publications - 44
Citations - 3829
José Luis González-Larriba is an academic researcher from Hospital Clínico San Carlos. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 16, co-authored 38 publications receiving 3517 citations.
Papers
More filters
Journal ArticleDOI
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell,Teresa Moran,Cristina Queralt,Rut Porta,Felipe Cardenal,Carlos Camps,Margarita Majem,Guillermo Lopez-Vivanco,Dolores Isla,Mariano Provencio,A. Insa,Bartomeu Massuti,José Luis González-Larriba,Luis Paz-Ares,Isabel Bover,Rosario García-Campelo,Miguel Angel Moreno,Silvia Catot,Christian Rolfo,Noemi Reguart,Ramon Palmero,Jose Miguel Sanchez,Roman Bastus,Clara Mayo,Jordi Bertran-Alamillo,Miguel Angel Molina,Jose Javier Sanchez,Miquel Taron +27 more
TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.
Journal ArticleDOI
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
Felipe Cardenal,M. Paz López-Cabrerizo,Antonio Antón,Vicente Alberola,Bartomeu Massuti,Alfredo Carrato,Isidoro Barneto,M. Lomas,Margarita García,Pilar Lianes,Joaquín Montalar,C. Vadell,José Luis González-Larriba,Binh Bui Nguyen,Angel Artal,Rafael Rosell +15 more
TL;DR: Compared with etoposide-cisplatin, gemcitabine-c isplatin provides a significantly higher response rate and a delay in disease progression without impairing QOL in patients with advanced NSCLC.
Journal ArticleDOI
Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
Enriqueta Felip,Rafael Rosell,José Maestre,José Manuel Rodríguez-Paniagua,Teresa Moran,Julio Astudillo,Guillermo Alonso,José Manuel Borro,José Luis González-Larriba,Antoni Torres,Carlos Camps,Ricardo Guijarro,Dolores Isla,Rafael Aguiló,Vicente Alberola,José Padilla,Abel Sánchez-Palencia,Jose Javier Sanchez,Eduardo Hermosilla,Bartomeu Massuti +19 more
TL;DR: In early-stage patients, no statistically significant differences in disease-free survival were found with the addition of preoperative or adjuvant chemotherapy to surgery in this phase III trial, in which the treatment decision was made before surgery.
Journal ArticleDOI
Paclitaxel Resistance in Non–Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations
Mariano Monzo,Rafael Rosell,Jose Javier Sanchez,Jin S. Lee,Aurora O'Brate,José Luis González-Larriba,Vicente Alberola,Juan Carlos Lorenzo,Laura Núñez,Jae Y. Ro,Cristina Martin +10 more
TL;DR: The mechanism that causes chemoresistance in non-small-cell lung cancer (NSCLC) patients has yet to be clearly elucidated as mentioned in this paper, and the mechanisms that cause chemoresistant in nonsmall-small cell lung cancer patients have not been elucidated.
Journal ArticleDOI
Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non–Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901
Pilar Garrido,José Luis González-Larriba,A. Insa,Mariano Provencio,Antoni Torres,Dolores Isla,Jose Miguel Sanchez,Felipe Cardenal,Manuel Domine,Jose Ramon Barcelo,Vicente Tarrazona,Andrés Varela,Rafael Aguiló,Julio Astudillo,Ignacio Muguruza,Angel Artal,F. Hernando-Trancho,Bartomeu Massuti,Maria Sanchez-Ronco,Rafael Rosell +19 more
TL;DR: Induction chemotherapy followed by surgery is effective in stage IIIA and in selected stage IIIB patients attaining complete resection, and age younger than 60 years (HR = 0.64) were the most powerful prognostic factors.